conditions fatty-liver

RECND562

Fatty Liver

Condition:Non-Alcoholic Fatty Liver Disease (NAFLD)
Other:Non-Alcoholic Steatohepatitis (NASH)
ICD-10 Codes:K76.0

Summary

Top 5 natural treatments for fatty liver disease:

1. artichoke (Cynara scolymus)
2. turmeric (Curcuma longa) and curcumin
3. vitamin B12 (methylcobalamin)
4. weight loss
5. bitter melon (Momordica charantia)

Naturopathic Treatments

Balance blood sugar with diet & exercise
• avoid refined sugars (fructose)
• do not over-eat
weight loss
• moderate exercise

Eat specific foods shown to help with fatty liver
• olive oil
• soy
• green tea
• tomato juice
• chlorella supplement
• red wine (in moderation)
• blueberries

Balance blood sugar with herbs
cinnamon (Cinnamomum verum)
bitter melon (Momordica charantia)

Improve ratio of good fats to bad fats
• increase omega-3 fatty acids (fish oil)
• avoid trans-fats
• avoid animal fat

Protect the liver and decrease inflammation:
turmeric (Curcuma longa)
ginger (Zingiber officinale)
• olive leaf (Olea europaea)
licorice (Glycyrrhiza glabra)

Decrease hepatic fat production and increase excretion
artichoke (Cynara scolymus)
milk thistle (Silybum marianum)
wild yam (Dioscorea villosa)

Increase methylation reactions
• S-adenosyl methionine (SAMe)
choline
Vitamin B12 (methylcobalamin)

Correct vitamin deficiencies
• increase sunlight exposure and/or vitamin D supplement
vitamin E
vitamin C

Asian formulas
Cinnamon and Hoelen Formula Extract (Keishi-bukuryo-gan; Gui Zhi Fu Ling Wan)

Topical Applications
• castor oil packs

Conventional Treatments

• no standard txt
• medication (thiazolidinediones, metformin, gemfibrozil, atorvastatin)
• surgery

Signs & Symptoms

• may be asymptomatic
• pain over the area of the liver
• loss of appetite
• weakness

DDx

cholelithiasis
• alcoholic fatty liver
hepatitis
• hemochromatosis
hypothyroidism
• celiac sprue
• cirrhosis
• drug-induced hepatotoxicity
• primary sclerosing cholangitis
• Wilson s disease
vitamin A toxicity

Pathogenesis

• changes in liver fat content that is not associated with alcohol consumption
• increased fat storage in the liver that is associated with insulin resistance
• dx excluded if consuming > 25 mL/day alcohol
• three types of nonalcoholic fatty liver disease:

Nonalcoholic fatty liver:
• elevated fat content in the liver without complications;

Nonalcoholic steatohepatitis (NASH):
• elevated fat content in the liver leading to inflammation, dysfunction and complications;

Nonalcoholic fatty liver disease-associated cirrhosis:
fatty liver induces chronic inflammation, leads to fibrosis and eventually liver failure;

Diagnostics

• liver function tests (ALT, ALP)
• ultrasound
• CT
• MRI
• biopsy (needle)
• FibroTest
• SteatoTest
• ELISA
• ESR
• glucose
• albumin
• kidney function
• serology test for hepatitis
• thyroid panel (especially TSH)
• platelet count, PTT, PT, fibrinogen

References

"Show references"

"Hide references"

Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Deretzi G,
Zavos C, Gavalas E, Katsinelos P, Mane V, Slavakis A. Serum homocysteine levels
in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2012
Jan-Feb;11(1):68-76. PubMed PMID: 22166563.

Cordero P, Campion J, Milagro FI, Martinez JA. Transcriptomic and epigenetic
changes in early liver steatosis associated to obesity: effect of dietary methyl
donor supplementation. Mol Genet Metab. 2013 Nov;110(3):388-95. doi:
10.1016/j.ymgme.2013.08.022. Epub 2013 Sep 17. PubMed PMID: 24084163.

1: Liu Y, Wang D, Zhang D, Lv Y, Wei Y, Wu W, Zhou F, Tang M, Mao T, Li M, Ji B.
Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced
hepatic steatosis in vitro. J Agric Food Chem. 2011 Nov 23;59(22):12254-63. doi:
10.1021/jf203136j. Epub 2011 Nov 1. PubMed PMID: 21999238.


2: Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits
on lipid profile, liver enzymes, insulin resistance, and high-sensitivity
C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014
Feb;34(2):143-8. doi: 10.1016/j.nutres.2013.11.005. Epub 2013 Dec 6. PubMed PMID:
24461315.


3: Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A.
Investigation of the effects of Chlorella vulgaris supplementation in patients
with non-alcoholic fatty liver disease: a randomized clinical trial.
Hepatogastroenterology. 2012 Oct;59(119):2099-2103. doi: 10.5754/hge10860. PubMed
PMID: 23234816.


4: Xu J, Cao K, Li Y, Zou X, Chen C, Szeto IM, Dong Z, Zhao Y, Shi Y, Wang J, Liu
J, Feng Z. Bitter gourd inhibits the development of obesity-associated fatty
liver in C57BL/6 mice fed a high-fat diet. J Nutr. 2014 Apr;144(4):475-83. doi:
10.3945/jn.113.187450. Epub 2014 Feb 12. PubMed PMID: 24523491.


5: Senanayake GV, Fukuda N, Nshizono S, Wang YM, Nagao K, Yanagita T, Iwamoto M,
Ohta H. Mechanisms underlying decreased hepatic triacylglycerol and cholesterol
by dietary bitter melon extract in the rat. Lipids. 2012 May;47(5):495-503. doi:
10.1007/s11745-012-3667-0. Epub 2012 Mar 29. PubMed PMID: 22457205.


6: Muraki E, Chiba H, Taketani K, Hoshino S, Tsuge N, Tsunoda N, Kasono K.
Fenugreek with reduced bitterness prevents diet-induced metabolic disorders in
rats. Lipids Health Dis. 2012 May 29;11:58. doi: 10.1186/1476-511X-11-58. PubMed
PMID: 22642742; PubMed Central PMCID: PMC3416582.


7: Shih CC, Shlau MT, Lin CH, Wu JB. Momordica charantia ameliorates insulin
resistance and dyslipidemia with altered hepatic glucose production and fatty
acid synthesis and AMPK phosphorylation in high-fat-fed mice. Phytother Res. 2014
Mar;28(3):363-71. doi: 10.1002/ptr.5003. Epub 2013 Apr 23. PubMed PMID: 23610006.


8: Hur W, Kim SW, Lee YK, Choi JE, Hong SW, Song MJ, Bae SH, Park T, Um SJ, Yoon
SK. Oleuropein reduces free fatty acid-induced lipogenesis via lowered
extracellular signal-regulated kinase activation in hepatocytes. Nutr Res. 2012
Oct;32(10):778-86. doi: 10.1016/j.nutres.2012.06.017. Epub 2012 Aug 9. PubMed
PMID: 23146775.


9: Sato M, Ueda T, Nagata K, Shiratake S, Tomoyori H, Kawakami M, Ozaki Y, Okubo
H, Shirouchi B, Imaizumi K. Dietary kakrol (Momordica dioica Roxb.) flesh
inhibits triacylglycerol absorption and lowers the risk for development of fatty
liver in rats. Exp Biol Med (Maywood). 2011 Oct;236(10):1139-46. doi:
10.1258/ebm.2011.011037. Epub 2011 Jul 26. PubMed PMID: 21791551.


10: Hajiaghamohammadi AA, Ziaee A, Samimi R. The efficacy of licorice root
extract in decreasing transaminase activities in non-alcoholic fatty liver
disease: a randomized controlled clinical trial. Phytother Res. 2012
Sep;26(9):1381-4. doi: 10.1002/ptr.3728. Epub 2012 Feb 6. PubMed PMID: 22308054.


11: Milosevi N, Milanovi M, Abenavoli L, Mili N. Phytotherapy and NAFLD--from
goals and challenges to clinical practice. Rev Recent Clin Trials.
2014;9(3):195-203. PubMed PMID: 25514914.


12: Yehuda I, Madar Z, Leikin-Frenkel A, Tamir S. Glabridin, An isoflavan from
licorice root, down-regulates iNOS expression and activity under high glucose
stress and inflammation. Mol Nutr Food Res. 2015 Mar 3. doi:
10.1002/mnfr.201400876. [Epub ahead of print] PubMed PMID: 25737160.


13: Ren T, Huang C, Cheng M. Dietary blueberry and bifidobacteria attenuate
nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling
pathway. Oxid Med Cell Longev. 2014;2014:469059. doi: 10.1155/2014/469059. Epub
2014 Nov 27. PubMed PMID: 25544867; PubMed Central PMCID: PMC4265704.


14: Vendrame S, Daugherty A, Kristo AS, Klimis-Zacas D. Wild blueberry (Vaccinium
angustifolium)-enriched diet improves dyslipidaemia and modulates the expression
of genes related to lipid metabolism in obese Zucker rats. Br J Nutr. 2014 Jan
28;111(2):194-200. doi: 10.1017/S0007114513002390. Epub 2013 Aug 6. PubMed PMID:
23920421.


15: Mouzaki M, Allard JP. The role of nutrients in the development, progression,
and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2012
Jul;46(6):457-67. doi: 10.1097/MCG.0b013e31824cf51e. Review. PubMed PMID:
22469640.




Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS, Scheimann AO. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012 Apr;95(4):892-900. Epub 2012 Feb 15. PubMed PMID: 22338037; PubMed Central PMCID: PMC3302364.

Salamone F, Galvano F, Marino A, Paternostro C, Tibullo D, Bucchieri F, Mangiameli A, Parola M, Bugianesi E, Li Volti G. Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis. 2012 Apr;44(4):334-42. Epub 2011 Dec 24. PubMed PMID: 22197629.

Omagari K, Kato S, Tsuneyama K, Hatta H, Sato M, Hamasaki M, Sadakane Y,Tashiro T, Fukuhata M, Miyata Y, Tamaru S, Tanaka K, Mune M. Olive leaf extractprevents spontaneous occurrence of non-alcoholic steatohepatitis in SHR/NDmcr-cp rats. Pathology. 2010 Jan;42(1):66-72. PubMed PMID: 20025483.

Takayama F, Nakamoto K, Totani N, Yamanushi T, Kabuto H, Kaneyuki T, MankuraM. Effects of docosahexaenoic acid in an experimental rat model of nonalcoholicsteatohepatitis. J Oleo Sci. 2010;59(8):407-14. PubMed PMID: 20625232.

Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. Thetherapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fattyliver disease. Clin Nutr. 2011 Feb;30(1):6-19. Epub 2010 Jul 8. PubMed PMID:20619513.

Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How differentis the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006Oct;25(5):816-23. Epub 2006 May 4. PubMed PMID: 16677739.

Yki-JÄrvinen H. Nutritional modulation of nonalcoholic fatty liver disease andinsulin resistance: human data. Curr Opin Clin Nutr Metab Care. 2010Nov;13(6):709-14. Review. PubMed PMID: 20842026.

Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role offructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat RevGastroenterol Hepatol. 2010 May;7(5):251-64. Epub 2010 Apr 6. Review. PubMedPMID: 20368739.

Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, Diehl AM;Nonalcoholic Steatohepatitis Clinical Research Network. Increased fructoseconsumption is associated with fibrosis severity in patients with nonalcoholicfatty liver disease. Hepatology. 2010 Jun;51(6):1961-71. PubMed PMID: 20301112;PubMed Central PMCID: PMC2922495.

Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, Yamaji R, Inui H, Fukusato T, Yamanouchi T. Rats fed fructose-enriched diets havecharacteristics of nonalcoholic hepatic steatosis. J Nutr. 2009Nov;139(11):2067-71. Epub 2009 Sep 23. PubMed PMID: 19776184.

Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitaminC treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am JGastroenterol. 2003 Nov;98(11):2485-90. PubMed PMID: 14638353.

Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplicationof results but lack of demonstration of efficacy. Am J Gastroenterol. 2003Nov;98(11):2348-50. PubMed PMID: 14638333.

Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int J Cancer. 2010 Apr 15;126(8):1788-96. PubMed PMID: 19551842; PubMed Central PMCID: PMC2829382.

Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, HÄussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). Eur J Med Res. 2011 Feb 24;16(2):76-8. PubMed PMID: 21463986; PubMed Central PMCID: PMC3353426.

Ahn J, Lee H, Jung CH, Ha T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res. 2012 Sep 12. doi: 10.1002/mnfr.201200182. [Epub ahead of print] PubMed PMID: 22968990.

Lupattelli G, Marchesi S, Lombardini R, Roscini AR, Trinca F, Gemelli F, Vaudo G, Mannarino E. Artichoke juice improves endothelial function in hyperlipemia. Life Sci. 2004 Dec 31;76(7):775-82. PubMed PMID: 15581909.

SaÉnz Rodriguez T, GarcÍa GimÉnez D, de la Puerta V Á zquez R. Choleretic activity and biliary elimination of lipids and bile acids induced by an artichoke leaf extract in rats. Phytomedicine. 2002 Dec;9(8):687-93. PubMed PMID: 12587687.

Kosters A, Frijters RJ, Kunne C, Vink E, Schneiders MS, Schaap FG, Nibbering CP, Patel SB, Groen AK. Diosgenin-induced biliary cholesterol secretion in mice requires Abcg8. Hepatology. 2005 Jan;41(1):141-50. PubMed PMID: 15619238.

Yamaguchi A, Tazuma S, Ochi H, Chayama K. Choleretic action of diosgenin is based upon the increases in canalicular membrane fluidity and transporter activity mediating bile acid independent bile flow. Hepatol Res. 2003 Mar;25(3):287-295. PubMed PMID: 12697250.

Accatino L, Pizarro M, SolÍs N, Koenig CS. Effects of diosgenin, a plant-derived steroid, on bile secretion and hepatocellular cholestasis induced by estrogens in the rat. Hepatology. 1998 Jul;28(1):129-40. PubMed PMID: 9657105.

Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.healthydigestionclinic.com © 2015 NDAssist Inc. and/or its affiliates. All rights reserved.